New York, NY, November 17, 2013 --(PR.com
)-- Today on the annual department meeting, Creative Biomart announces that it plans to invest more than $300 million to strengthen its biosimilar cell lines production in global range.
The domain sectors of Creative Biomart are recombinant proteins, antibodies and enzymes. Several years ago, the company decided to introduce biosimilar cell lines production and soon it became a pioneer and undisputed global leader in the rapidly emerging market.
Creative Biomart has developed a comprehensive range of biosimilar stable cell lines based on its proprietary gene screening and amplification system. And these cell lines have been accepted by CMO's and manufacturers worldwide to produce cGMP material also.